This combination medication is used across therapeutic domains involving cardiovascular strain, and generally applies to patients whose conditions require the complementary action of two agents.

Stamlo Beta is commonly used for the chronic, daily management of high blood pressure (Hypertension), and is also considered relevant for patients with Chronic Stable Angina Pectoris, a condition characterized by recurrent chest pain or discomfort. The medication is applied in addressing symptoms that create noticeable physiological strain caused by persistently elevated pressure. The therapeutic benefit supports maintaining a sense of stability when symptoms are more noticeable, and this may assist with reducing the risk of cardiovascular events. The medication is relevant when additional symptomatic support is needed because the patient’s clinical profile is commonly used to help with symptoms related to systemic imbalance. This is often used when a patient's condition is uncontrolled by a single medication.

“The therapeutic relevance of this combination therapy is that it provides support that helps ease the overall symptom burden, contributing to a more stable circulatory status.”

Quick Fact: Relief for Recurrent Cardiac Discomfort The benefit helps address symptom clusters that may become intense or disruptive, which assists with maintaining functional stability and supports general well-being during symptomatic phases, and is commonly used to help with symptoms associated with acute or episodic changes.

Regulatory References

1. NIH MedlinePlus Drug Information

This section outlines the officially documented patient eligibility and non-eligibility for the combination medicine Stamlo Beta (Amlodipine and Atenolol), based strictly on government regulatory documents.

Contraindicated Populations (Must Not Use)

The medicine is formally contraindicated and must not be used by patients presenting with:

• Hypersensitivity or Allergy to Amlodipine, Atenolol, or any other beta-blocker or dihydropyridine calcium antagonist.
• Cardiogenic Shock or Severe Heart Failure (uncontrolled/decompensated).
• Severe Hypotension (very low blood pressure).
• Second- or Third-Degree Atrioventricular (AV) Block or Sick Sinus Syndrome (unless a functioning pacemaker is present).
• Metabolic Acidosis or Untreated Phaeochromocytoma.
• Severe Bronchial Asthma or other severe obstructive airway diseases.

Restricted or Conditional Use (Caution Required)

Use is restricted or requires special medical caution and dose adjustment in:

• Patients with Hepatic or Renal Impairment (due to reduced drug clearance).
• Elderly Patients (a lower starting dose is usually recommended).
• Patients with First-Degree AV Block, Diabetes Mellitus, or Peripheral Arterial Disease.

Age and Reproductive Status

• Pediatric Patients: Use in children and adolescents (under 18 years) is not recommended due to insufficient data on safety and efficacy.
• Pregnancy and Lactation: Use is generally not recommended during pregnancy (often listed as Category D or similar restriction) or while breastfeeding, as components can be excreted in breast milk.

Interactions with other medicines and products

Stamlo Beta, which contains Amlodipine and Atenolol, has documented interactions that can affect its concentration in the body or alter its primary effect on blood pressure and heart rate, as detailed in regulatory prescribing information.

Medicinal Product Interactions

The co-administration of Stamlo Beta with certain medicines may be classified by regulatory authorities as requiring caution or restriction:

• CYP3A4 Modulators: Strong inhibitors of the CYP3A4 enzyme, such as the antifungals Ketoconazole and Itraconazole, can increase Amlodipine plasma concentration. Conversely, CYP3A4 inducers like Rifampin or Phenytoin may decrease its concentration.
• Cardiovascular Agents: Other agents that lower blood pressure, including non-dihydropyridine calcium channel blockers (e.g., Verapamil) and antiarrhythmics, can produce additive pharmacodynamic effects on the heart rate and blood pressure.
• Simvastatin: The maximum dose of the cholesterol-lowering medicine Simvastatin must be limited when used concurrently with Amlodipine due to increased exposure risk.

Interactions with Food and Supplements

Official regulatory documents advise on certain interactions involving non-drug products:

• Grapefruit Juice and Alcohol: Consumption is advised against as both can lead to an increased effect of the medicine, potentially causing an excessive drop in blood pressure.
• Multivitamin with Minerals: Co-administration may decrease the desired effect of the Atenolol component. Regulatory advice dictates separating the administration of the medicine and the supplement by at least two hours.

Population-specific caution regarding interactions is formally noted for patients with hepatic impairment, as their reduced liver function may increase the potential for Amlodipine accumulation.

Stamlo Beta is a fixed-dose combination composed of amlodipine and metoprolol succinate, each modulating distinct physiological systems. The amlodipine component is a dihydropyridine calcium channel blocker. Its mechanism involves inhibiting the transmembrane influx of calcium ions into both vascular smooth muscle and cardiac muscle cells. This inhibition results in vasodilation and a subsequent decrease in peripheral vascular resistance. The metoprolol succinate component functions as a selective beta1-adrenergic receptor antagonist. It achieves its effect by competitively blocking beta1-receptors located predominantly in the heart. This antagonism leads to a decrease in heart rate (negative chronotropic effect) and a reduction in myocardial contractility (negative inotropic effect). These dual actions converge to induce a decrease in myocardial oxygen consumption and a reduction of cardiac workload.

How to Use Stamlo Beta: Official Administration Guidelines

Stamlo Beta is a prescription-only, fixed-dose combination product that must be used strictly according to the regimen defined by regulatory authorities. The official instructions govern the route, daily schedule, dosing limits, and required procedural constraints.

The route of administration is oral only. This medicine is typically taken once daily at a fixed time to ensure consistent blood plasma levels. Stamlo Beta can be administered with or without food.

Population and Procedural Constraints

Due to the components' pharmacokinetic profiles, specific adjustments are mandated for certain patient populations. For older adults and those with hepatic impairment, a lower initial dose of the Amlodipine component (e.g., 2.5 mg equivalent) and cautious titration are required. Similarly, renal impairment necessitates dose adjustments for the Atenolol component.

The procedural structure dictates that the tablet must be swallowed whole and must not be crushed, broken, or chewed. Furthermore, treatment should never be stopped abruptly. The dose must be gradually reduced over a period of time under medical observation due to the risk associated with sudden withdrawal of the Beta-blocker component. This gradual tapering requirement defines the end-of-use protocol.

Research Evidence / Overview of Studies for Stamlo Beta

Evidence for Managing High Blood Pressure (Hypertension)

Research examining the combination for the management of essential hypertension primarily relies on randomized controlled trials (RCTs) and comprehensive systematic reviews. Research was evaluated in trials that compared the fixed-dose regimen against treatment with either amlodipine or atenolol alone (monotherapy).

The studies monitored outcomes related to physiological strain or stress, focusing heavily on measurements of changes in Systolic and Diastolic Blood Pressure (BP) and whether specific measurement thresholds were achieved by participants. Trials typically involved adults with essential hypertension, often those whose condition was studied for responses when not adequately managed by a single medication.

Evidence for Chronic Stable Angina Pectoris

Studies explored the use of this medicine in conditions characterized by functional limitations, specifically chronic stable angina pectoris. The research primarily consists of randomized controlled trials (RCTs) and crossover trials that studies monitored patient responses over defined time intervals.

Researchers examined outcomes related to physical discomfort and functional capacity. These outcomes included the number and frequency of angina attacks and the measurements of exercise tolerance. The research focused on populations of adults with stable angina pectoris who met the criteria for enrollment.

What Research Gaps and Uncertainties Remain

The research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain.

Data for certain groups remain insufficient, as the majority of research included adult populations. There is limited information for long-term outcomes that measure the drug’s effect on hard clinical events. Furthermore, comparative evidence is lacking when assessing this combination against newer fixed-dose therapies that use different drug classes. Findings were based on study results that reflect the specific conditions under which they were conducted, and evidence quality varies across studies focusing on different populations and endpoints.

Key Studies & References

1. Effect of amlodipine and atenolol on blood pressure and heart rate in essential hypertensive subjects: a systematic review and meta-analysis
2. Amlodipine plus Atenolol Versus Amlodipine Monotherapy in Ambulatory Systolic Hypertension (Clinical Trial Record)
3. Amlodipine and Atenolol Combination: MedlinePlus Drug Information (Contextual Reference)

Common questions about Stamlo Beta (FAQ)

Q: What should I do if I miss a dose of Stamlo Beta?

According to official product information, if a dose of this once-daily medicine is missed, instructions state that it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. Product labeling warns that a double dose should not be taken to compensate for a forgotten one.

Q: Does Stamlo Beta interact with common pain relievers like Ibuprofen or Acetaminophen?

Regulatory documents indicate that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Ibuprofen, may reduce the blood pressure-lowering effect of the Atenolol component. This potential interaction is primarily noted for chronic, long-term use of NSAIDs. Official drug labels do not generally list a specific interaction for Acetaminophen.

Q: How long after starting the medication should I expect to see my blood pressure improve?

The full therapeutic response to any specific dose of Stamlo Beta may not be fully apparent immediately. Official administration guidelines suggest that the interval between dose changes should be about 7 to 14 days. This time is suggested to allow for a full assessment of the drug’s response.

Q: What distinguishes this combined drug from taking Amlodipine and Atenolol separately?

Stamlo Beta is manufactured as a fixed-dose combination product, combining two active ingredients into a single tablet. This approach uses the complementary actions of the two different drug classes to simplify the dosing regimen for the patient. Combination therapy is typically initiated when a patient’s condition has not been adequately controlled by a single medication alone.

How to Store and Dispose of Stamlo Beta?

The storage of Stamlo Beta (amlodipine/atenolol) must comply with official regulatory labeling to ensure product stability and safety.

The medicine must always be kept out of the sight and reach of children. Unused or expired tablets should be disposed of via a drug take-back program. If this is unavailable, the product should be mixed with an unappealing substance and sealed in a bag before discarding in household trash; the product must not be flushed down a toilet or poured down a drain.